1. Antibiotics in the clinical pipeline at the end of 2015
2. Antibiotics in late clinical development
3. World
Health Organization. (2017) Antibacterial agents in clinical development: An analysis of the
antibacterial clinical development pipeline, including tuberculosis, WHO/EMP/IAU/2017.11, WHO, Geneva, http://apps.who.int/iris/bitstream/10665/258965/1/WHO-EMP-IAU-2017.11-eng.pdf?ua=1 (accessed 22 November 2017).
4. Grayeff, Y. (2014) Cubist Q4 revenues + 22%; Cubicin annual sales top $1B, https://seekingalpha.com/news/1503931-cubist-q4-revenues-plus-22-percent-cubicin-annual-sales-top-1b (accessed 22 November 2017).
5. CDC. (2013) Antibiotic Resistance Threats in the
United States, 2013, U.S. Department of Health
and Human Services (Centers for Disease Control and Prevention), Atlanta, http://www.cdc.gov/drugresistance/threat-report-2013 (accessed 22 November 2017).